# Mounjaro May Lead to Greater Lean Body Mass Loss than Ozempic
Mounjaro appears to cause more loss of lean muscle tissue compared to Ozempic, a distinction that matters for people choosing between these popular weight loss drugs.
Both medications belong to the GLP-1 receptor agonist class and work by slowing digestion and reducing appetite. The difference lies in their active ingredients. Mounjaro contains tirzepatide, which targets two hormone receptors. Ozempic uses semaglutide, which targets one.
Recent clinical data shows Mounjaro users experienced greater overall weight loss than Ozempic users in head-to-head trials. However, this additional weight loss includes more lean muscle mass, not just fat. This distinction carries real consequences. Losing muscle weakens bones, reduces metabolism, and increases injury risk.
When people lose weight rapidly without resistance training, they naturally shed muscle along with fat. GLP-1 drugs amplify this effect by reducing appetite so severely that users struggle to consume enough protein. Protein intake becomes critical for preserving muscle during weight loss.
Healthcare providers recommend several strategies to minimize lean mass loss. Resistance training two to three times weekly helps preserve muscle fibers. Consuming adequate protein, roughly 1.2 to 2.2 grams per kilogram of body weight daily, supports muscle retention. Gradual weight loss over time allows the body to preserve lean tissue better than rapid drops.
Neither drug automatically causes excessive muscle loss. The outcome depends on how people use them. Someone taking Mounjaro while strength training and eating sufficient protein will retain more muscle than someone using Ozempic without exercise or adequate nutrition.
The choice between these medications involves weighing total weight loss benefits against potential muscle preservation concerns. People considering either drug should discuss muscle health with their doctor and develop a plan combining